The Radioimmunoassay Market was valued at USD 1.51 Billion in 2024, and is projected to reach USD 1.79 Billion by 2030, rising at a CAGR of 2.93%. The market growth is driven by its critical role in highly sensitive and specific diagnostic applications. RIA remains a major solution for the detection of minute concentrations of hormones, drugs, tumor markers, and infectious agents despite the rise of newer immunoassay techniques. A key market driver is the rising prevalence of chronic and infectious diseases worldwide. According to UNAIDS, nearly 39.9 million people globally were living with HIV in 2023, with 1.3 million new infections, reflecting the ongoing need for accurate and reliable testing methodologies such as RIA. In addition, the increasing incidence of thyroid disorders and certain cancers has amplified the demand for precise endocrine and oncology diagnostics.
Recent advancements in RIA technologies and reagents have also contributed to market growth. Companies such as Medipan GmbH have enhanced the shelf life of RIA kits for TSH, Tg, and Calcitonin, improving laboratory efficiency. Additionally, their streamlined SELco TRAb 1-step assay, launched in 2022, has improved turnaround time and workflow simplicity in detecting thyroid antibodies. Strategic collaborations and acquisitions further highlight market consolidation and innovation. For instance, DiaSorin’s acquisition of Luminex Corporation has expanded its multiplex testing capabilities, reinforcing its position in specialty diagnostics, including RIA. Moreover, DIAsource's milestone agreement with Svar Life Science (formerly Euro Diagnostica) supports the development of advanced immunoassay solutions, further boosting RIA technology dissemination.
The radioimmunoassay market is also shaped by its relevance in both clinical diagnostics and research. Clinical settings, especially hospitals and diagnostic laboratories, account for a substantial market share due to the routine use of RIA in hormonal assays and allergy testing. Meanwhile, research laboratories drive the fastest growth, utilizing RIA’s high specificity for biomedical studies. The introduction of advanced analyzers and automated gamma counters, like those from LabLogic Systems, supports the modernization of RIA workflows and widens access to high-throughput applications.
Advancements in lab-on-a-chip (LOC) technology have revolutionized traditional radioimmunoassay (RIA). The development of microfluidic RIA platforms, or μ-RIA, has significantly reduced analysis times to approximately five minutes and minimized reagent consumption. These improvements address previous limitations of RIA, such as lengthy incubation periods and radioactive waste production, thereby enhancing the technique's applicability in clinical diagnostics. These developments underscore a concerted effort to refine radioactive labeling and radioimmunoassay methodologies, aiming for greater precision, efficiency, and safety in diagnostic imaging and targeted. Recently, in March 2025, researchers from the University of Alberta introduced a novel molecular imaging test that combines the monoclonal antibody panitumumab with the radioisotope copper-64. Panitumumab targets the epidermal growth factor receptor (EGFR), commonly overexpressed in non-small-cell lung cancer cells. When labeled with copper-64, this conjugate enables precise PET imaging, facilitating early detection and monitoring of lung cancer. This hybrid approach offers a non-invasive alternative to traditional biopsies, potentially improving patient outcomes through timely intervention.
This product will be delivered within 1-3 business days.
Recent advancements in RIA technologies and reagents have also contributed to market growth. Companies such as Medipan GmbH have enhanced the shelf life of RIA kits for TSH, Tg, and Calcitonin, improving laboratory efficiency. Additionally, their streamlined SELco TRAb 1-step assay, launched in 2022, has improved turnaround time and workflow simplicity in detecting thyroid antibodies. Strategic collaborations and acquisitions further highlight market consolidation and innovation. For instance, DiaSorin’s acquisition of Luminex Corporation has expanded its multiplex testing capabilities, reinforcing its position in specialty diagnostics, including RIA. Moreover, DIAsource's milestone agreement with Svar Life Science (formerly Euro Diagnostica) supports the development of advanced immunoassay solutions, further boosting RIA technology dissemination.
The radioimmunoassay market is also shaped by its relevance in both clinical diagnostics and research. Clinical settings, especially hospitals and diagnostic laboratories, account for a substantial market share due to the routine use of RIA in hormonal assays and allergy testing. Meanwhile, research laboratories drive the fastest growth, utilizing RIA’s high specificity for biomedical studies. The introduction of advanced analyzers and automated gamma counters, like those from LabLogic Systems, supports the modernization of RIA workflows and widens access to high-throughput applications.
Advancements in lab-on-a-chip (LOC) technology have revolutionized traditional radioimmunoassay (RIA). The development of microfluidic RIA platforms, or μ-RIA, has significantly reduced analysis times to approximately five minutes and minimized reagent consumption. These improvements address previous limitations of RIA, such as lengthy incubation periods and radioactive waste production, thereby enhancing the technique's applicability in clinical diagnostics. These developments underscore a concerted effort to refine radioactive labeling and radioimmunoassay methodologies, aiming for greater precision, efficiency, and safety in diagnostic imaging and targeted. Recently, in March 2025, researchers from the University of Alberta introduced a novel molecular imaging test that combines the monoclonal antibody panitumumab with the radioisotope copper-64. Panitumumab targets the epidermal growth factor receptor (EGFR), commonly overexpressed in non-small-cell lung cancer cells. When labeled with copper-64, this conjugate enables precise PET imaging, facilitating early detection and monitoring of lung cancer. This hybrid approach offers a non-invasive alternative to traditional biopsies, potentially improving patient outcomes through timely intervention.
Radioimmunoassay Market Report Highlights
- The reagent and kits led the product segment in 2024 with a 73.23% revenue share. The increasing demand for reliable diagnostic tools in endocrine, oncology, infectious disease, and autoimmune disorder testing has significantly boosted the consumption of RIA reagents and kits across laboratories and hospitals. These kits typically include radioactively labeled antigens or antibodies (commonly using Iodine-125), buffers, standards, and separation reagents. The high sensitivity and specificity of these kits make them indispensable in clinical laboratories for detecting hormones such as TSH, insulin, cortisol, testosterone, and estradiol. For example, PerkinElmer and DIAsource ImmunoAssays offer a wide range of RIA kits for thyroid function testing (like TSH and Calcitonin), fertility hormones, and tumor markers, supporting routine screening and specialized diagnostics. Whereas analyzers is expected to be the fastest-growing segment during the forecast period.
- The clinical diagnostics led the application segment in the radioimmunoassay industry in 2024 with a 76.33% share in terms of revenue, owing to the widespread use of RIA techniques for routine and specialized medical testing. This dominance is primarily attributed to the method’s exceptional sensitivity and specificity in detecting minute concentrations of biological markers, making it invaluable for accurate diagnosis, disease monitoring, and therapeutic decision-making. Whereas research is expected to be the fastest-growing segment during the forecast period.
- The hospital led the end use segment in the market in 2024 with a 32.54% revenue share, driven by the hospitals’ comprehensive diagnostic capabilities and the increasing prevalence of diseases requiring precise biomarker detection. RIA's exceptional sensitivity and specificity make it indispensable in hospital settings for accurately measuring low concentrations of hormones, drugs, and other substances in patient samples. In addition, the adoption of automated and advanced RIA systems in hospitals has streamlined workflows, reduced turnaround times, and improved result accuracy.
- North America dominated the global market for radioimmunoassay with a revenue share of 47.43% in 2024. The growth is driven by the presence of advanced healthcare infrastructure, robust research and development (R&D) activities, and a high prevalence of chronic diseases necessitating precise diagnostic tools. Further, supportive policies and reimbursement frameworks enhance the adoption and integration of RIA in clinical diagnostics.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Radioimmunoassay Market Variables, Trends, & Scope
Chapter 4. Radioimmunoassay Market: Product Estimates & Trend Analysis
Chapter 5. Radioimmunoassay Market: Application Estimates & Trend Analysis
Chapter 6. Radioimmunoassay Market: End Use Estimates & Trend Analysis
Chapter 7. Radioimmunoassay Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Radioimmunoassay market report include:- DIAsource
- Tecan Trading AG
- PerkinElmer
- DRG International Inc.
- Oxford BioSystems
- DiaSorin S.p.A.
- Eurodiagnóstico, S.L.
- MP Biomedicals
- Merck KGaA
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 320 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.51 Billion |
| Forecasted Market Value ( USD | $ 1.79 Billion |
| Compound Annual Growth Rate | 2.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
